Lyme disease biology
- Borrelia burgdorferi:A spirochaete bacterium transmitted by Ixodes ticks. Following inoculation, disseminates haematogenously to joints, nervous system, and cardiac tissue. Erythema migrans rash (expanding bull’s-eye) is pathognomonic when present; absent in many cases.
- Neurological Lyme (neuroborreliosis):CNS invasion by Borrelia causes meningitis, encephalopathy, cranial nerve palsies (particularly facial nerve palsy), and radiculopathy. European Lyme (B. afzelii, B. garinii) is more neurotropic than North American B. burgdorferi.
- Post-Treatment Lyme Disease Syndrome (PTLDS):15–20% of patients treated with standard antibiotics continue to have fatigue, cognitive symptoms (“brain fog”), musculoskeletal pain, and sleep disturbance — sometimes for years. This is distinct from active persistent infection (not supported by evidence in antibiotic-treated patients). The dominant hypothesis is that microglial activation and neuroinflammation persist after bacterial clearance, triggered by the initial infection but not requiring ongoing bacterial presence.
Neuroinflammation in PTLDS
PET imaging and CSF studies in PTLDS patients demonstrate:
- Elevated microglial activation markers (TSPO binding on PET) in brain regions associated with fatigue and cognitive processing (default mode network, prefrontal cortex)
- Elevated IL-6, TNF-α, and CXCL13 in CSF of some PTLDS patients — indicating ongoing CNS inflammatory signalling
- Oxidative stress markers (8-OHdG) elevated in PTLDS plasma — consistent with NOX2-driven ROS generation
Phycocyanobilin relevance to PTLDS
- Phycocyanobilin crosses the blood-brain barrier and inhibits NOX2 in microglia — directly targeting the proposed PTLDS mechanism
- Reduction of microglial NF-κB activation reduces IL-6 and TNF-α output from activated microglia — the cytokines elevated in PTLDS CSF
- No clinical trial of spirulina or phycocyanin in PTLDS exists. The mechanistic case is directly applicable; the clinical evidence gap is standard for this class of neuroinflammatory condition.
Acute Lyme treatment compatibility
During antibiotic treatment (doxycycline, amoxicillin, cefuroxime for early Lyme; IV ceftriaxone for neuroborreliosis):
- No pharmacokinetic interaction between spirulina compounds and doxycycline, amoxicillin, ceftriaxone, or cefuroxime has been identified
- Doxycycline absorption is not affected by spirulina’s calcium content at normal doses (spirulina calcium at 5–10 g: 60–170 mg — below the threshold of clinical concern for doxycycline chelation, which is primarily relevant to dairy products)
- NK cell stimulation by spirulina during active bacterial infection is generally supportive rather than counterproductive — NK cells contribute to Borrelia clearance
Co-infections
Tick-borne co-infections are common in Lyme-endemic areas:
- Babesia:Intraerythrocytic parasite causing haemolytic anaemia. Iron management note: haemolysis releases iron from red cells — ferritin should be checked; iron supplementation (including spirulina iron) may or may not be appropriate depending on iron status post-haemolysis.
- Bartonella:Causes vasculoproliferative lesions and endothelial activation. Phycocyanobilin’s endothelial NOX2 inhibition is mechanistically relevant. Treatment typically involves doxycycline or azithromycin; no spirulina interaction.
- Ehrlichia/Anaplasma:Both treated with doxycycline; compatibility with spirulina as above.
Practical guidance
- During active antibiotic treatment: spirulina is compatible with standard Lyme antibiotics; 5–10 g/day is appropriate
- PTLDS (post-treatment persistent symptoms): spirulina’s phycocyanobilin is the most mechanistically targeted approach — focus on phycocyanin-preserving formats (cold preparations)
- Check ferritin — particularly if co-infections caused haemolysis; iron status may be elevated or deficient depending on the clinical course
- Inform managing infectious disease or Lyme-literate physician of all supplements